Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 4Lung Neoplasms 3Uterine Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Advanced Malignant Solid Neoplasm 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple-negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Previously Treated Non Small Cell Lung Cancer 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Lymphoid Interstitial Pneumonia 1Leukemia, Myelomonocytic, Chronic 1

Interventions

adavosertib 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Triple-negative Metastatic Breast Cancer × adavosertib × Clear all
NCT03012477 2021-11-23

CISPLATIN + AZD-1775 In Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
34 enrolled 9 charts
Breast

Triple-negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡